MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
MBOT - Microbot Medical Inc
$7.55
-0.38(-4.79%)4:14:53 PM 3/5/2021
Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data
Peers

Stock news

    02/4/2021MBOT
    Microbot Medical Granted Patent Allowance in Japan; Global Jurisdictions Recognizing Novel ‘One & Done’ Technology

    HINGHAM, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has received official notification from the Japan Patent Office (JPO) that it intends to grant the Company a patent for its ‘One & Done’ guidewire technology for use with endoluminal interventions. Japan is the second jurisdiction to grant a patent for the ‘One & Done’ guidewire technology and further protects the novel technology the Company is currently developing. “We are advancing our LIBERTY™ Robotic syst...

    01/27/2021MBOT
    Microbot Medical Announces Successful Outcome of its Discussions with FDA Regarding Regulation of Self-Cleaning Shunt

    FDA Feedback Reflects Strength of Pre-Clinical Safety Data; Maintains Q3 2022 Projected Commencement of First-in-Human Clinical TrialHINGHAM, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced the completion of successful discussions with the U.S. Food and Drug Administration (FDA) for its Self-Cleaning Shunt (SCS). After review of the Company’s existing pre-clinical data, the FDA’s feedback will allow the Company to apply for a limited clinical investigation...

    01/21/2021MBOT
    Microbot Medical Enhances Scientific Advisory Board with World Renowned Interventional Radiologists

    Scientific Advisory Board Expanded with Additions of Global Medical Pioneers and Distinguished Thought LeadersHINGHAM, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to enhance its thought leadership capabilities with the addition of several new Scientific Advisory Board (SAB) members: Stephen B. Solomon, MD, a board-certified radiologist with clinical expertise in Interventional Radiology with a focus in Tumor Ablation; Ajay K. Wakhloo, MD PhD FAHA, an i...

    01/14/2021MBOT
    Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTYTM Robotic System

    Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events Management Presenting at Needham Growth Conference Today at 2:00pm ETHINGHAM, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- The continued progression of Microbot Medical Inc.’s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world’s first fully disposable surgical robotic system. Th...

    01/11/2021MBOT
    Microbot Medical Demonstrates Significant Progress in 2020; Outlines Anticipated Milestones for 2021

    HINGHAM, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq CM: MBOT) has concluded 2020 with the achievement of several operating and developmental milestones. The Company believes it is well positioned to leverage and capitalize upon this momentum through 2021, with plans to execute additional developmental, regulatory and clinical goals.Key 2020 Operational and Product Achievements * Officially unveiled the LIBERTY™ Robotic System, the world’s first fully disposable surg...

    01/7/2021MBOT
    Microbot Medical to Share Current Progress and Expected 2021 Milestones at Upcoming Conferences

    HINGHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that Harel Gadot, CEO, President and Chief Executive Officer, will be presenting virtually at two upcoming investor conferences. Mr. Gadot will review the Company’s recent achievements, current progress and expected 2021 milestones. * HCW Wainwright Bioconnect Conference. Mr. Gadot will be participating in a fireside chat (Q&A session) and for those registered for the conference a video will be a...

    12/28/2020MBOT
    We Think Microbot Medical (NASDAQ:MBOT) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

    11/17/2020MBOT
    Microbot Medical Secures Patents in Multiple Global Jurisdictions

    HINGHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has received patents in multiple jurisdictions, further demonstrating the Company’s continued execution of expanding and protecting its Intellectual Property (IP) portfolio. The Company now has 40 issued/allowed patents and 23 patent applications pending worldwide. “As we continue to make progress on the development, clinical and regulatory fronts, it is encouraging that we are also achievin...